

Renuka P Limgala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/936786/publications.pdf>

Version: 2024-02-01

17
papers

452
citations

933447

10
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

652
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants. <i>JIMD Reports</i> , 2021, 59, 60-68.	1.5	5
2	Pregnancy Outcomes in Late Onset Pompe Disease. <i>Life</i> , 2020, 10, 194.	2.4	4
3	The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7213.	4.1	1
4	Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease. <i>Biomolecules</i> , 2020, 10, 526.	4.0	9
5	Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 1683-1696.	0.0	3
6	Enzyme replacement therapy reverses B lymphocyte and dendritic cell dysregulations in patients with Gaucher Disease. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 81-85.	1.4	5
7	Gaucheromas: When macrophages promote tumor formation and dissemination. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 68, 100-105.	1.4	25
8	Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. <i>PLoS ONE</i> , 2016, 11, e0168135.	2.5	25
9	Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 59, 8-15.	1.4	19
10	A Pilot Study of Omalizumab in Eosinophilic Esophagitis. <i>PLoS ONE</i> , 2015, 10, e0113483.	2.5	114
11	Diffuse Cutaneous Mastocytosis, Bullous Variant, Presenting in a Six-Month-Old Infant. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 341-342.	3.8	2
12	Efficient Procurement of Epithelial Stem Cells from Human Tissue Specimens Using a Rho-Associated Protein Kinase Inhibitor Y-27632. <i>Tissue Engineering - Part A</i> , 2010, 16, 1363-1368.	3.1	64
13	Human ribosomal protein L18a interacts with hepatitis C virus internal ribosome entry site. <i>Archives of Virology</i> , 2006, 151, 509-524.	2.1	19
14	A Peptide Derived from RNA Recognition Motif 2 of Human La Protein Binds to Hepatitis C Virus Internal Ribosome Entry Site, Prevents Ribosomal Assembly, and Inhibits Internal Initiation of Translation. <i>Journal of Virology</i> , 2005, 79, 9842-9853.	3.4	21
15	La Protein Binding at the GCAC Site Near the Initiator AUG Facilitates the Ribosomal Assembly on the Hepatitis C Virus RNA to Influence Internal Ribosome Entry Site-mediated Translation. <i>Journal of Biological Chemistry</i> , 2004, 279, 29879-29888.	3.4	48
16	Leader RNA of Rinderpest virus binds specifically with cellular La protein: a possible role in virus replication. <i>Virus Research</i> , 2004, 104, 101-109.	2.2	17
17	Hepatitis C Virus Internal Ribosome Entry Site-mediated Translation Is Stimulated by Specific Interaction of Independent Regions of Human La Autoantigen. <i>Journal of Biological Chemistry</i> , 2003, 278, 12231-12240.	3.4	71